Get started
Author

Sau-Chi Betty Yan

Observed names: S B Yan, S Betty Yan, S. B. Yan, S. Betty Yan, S. Yan, S.B Yan, S.B. YAN, S.B. Yan, S.Betty Yan, S. Betty Yan, Sau-Chi B. Yan, Sau-chi B Yan, Sau-chi B. Yan, Sau-chi Betty Yan, Sau-chi Yan, Sau‐Chi B Yan
Observed institutions: Scripps Research Institute, Bowling Green State University, Eli Lilly (United States), Iowa State University, Medical College of Wisconsin, University of Münster, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Jilin Province Tumor Hospital, University Hospital Münster, Institut Cochin, Université Paris Descartes
OpenAlex ID: A5111669144
Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation
2004 · J.‐F. Dhainaut, S.B. Yan, et al. · Journal of Thrombosis and Haemostasis · 419
Protein C levels as a prognostic indicator of outcome in sepsis and related diseases
2000 · Charles J. Fisher, S. Betty Yan · Critical Care Medicine · 416
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]
2004 · Gary T Kinasewitz, S Betty Yan, et al. · Critical Care · 361
PDF
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis
2001 · Gordon R. Bernard, E. Wesley Ely, et al. · Critical Care Medicine · 267
Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis
2001 · S. Betty Yan, Jeffrey D. Helterbrand, et al. · CHEST Journal · 254
Human Protein C inhibits selectin-mediated cell adhesion: role of unique fucosylated oligosaccharide
1994 · Brian W. Grinnell, Robert B. Hermann, et al. · Glycobiology · 225
Coagulopathy After Successful Cardiopulmonary Resuscitation Following Cardiac Arrest
2005 · Christophe Adrie, Mehran Monchi, et al. · Journal of the American College of Cardiology · 212
Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications
2000 · Rolf M. Mesters, Jeff Helterbrand, et al. · Critical Care Medicine · 197
Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)
2003 · Steven M. Opal, Gary E. Garber, et al. · Clinical Infectious Diseases · 192
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
2012 · S. Betty Yan, Victoria L. Peek, et al. · Investigational New Drugs · 173
PDF
Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia
2003 · Bryce A. Kerlin, S. Betty Yan, et al. · Blood · 169
Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever
2007 · Lisa E. Hensley, Edward L. Stevens, et al. · The Journal of Infectious Diseases · 157
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis
2003 · S. Yan, Benjamin Margolis, et al. · Thrombosis and Haemostasis · 118
Activated protein C versus protein C in severe sepsis
2001 · S. Betty Yan, Jean-François Dhainaut · Critical Care Medicine · 104
New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).
2005 · William L Macias, S Betty Yan, et al. · Critical Care · 98
PDF
Troponin-I as a prognosticator of mortality in severe sepsis patients
2010 · Jijo John, D. Bradley Woodward, et al. · Journal of Critical Care · 96
Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies
2005 · Jean-Louis Vincent, Simon Nadel, et al. · Critical Care · 73
PDF
Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
2013 · Wenjuan Wu, Chen Bi, et al. · Clinical Cancer Research · 67
Trans–Activated Expression of Fully Gamma–Carboxylated Recombinant Human Protein C, an Antithrombotic Factor
1987 · Brian W. Grinnell, David T. Berg, et al. · Nature Biotechnology · 58
Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C
2004 · S. Betty Yan, David R. Nelson · Critical Care Medicine · 56
Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis
2002 · Jean-François Dhainaut, S. Betty Yan, et al. · Critical Care Medicine · 55
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
2018 · Bruce W. Konicek, Andrew R. Capen, et al. · Oncotarget · 54
PDF
Dibasic Benzo[b]thiophene Derivatives as a Novel Class of Active Site-Directed Thrombin Inhibitors. 1. Determination of the Serine Protease Selectivity, Structure−Activity Relationships, and Binding Orientation
1997 · Daniel J. Sall, Jolie A. Bastian, et al. · Journal of Medicinal Chemistry · 54
Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling
2004 · Wei Zeng, William F. Matter, et al. · Critical Care Medicine · 53
Recombinant human protein C derivatives: altered response to calcium resulting in enhanced activation by thrombin.
1990 · H. J. Ehrlich, B. W. Grinnell, et al. · The EMBO Journal · 47
PDF
Works count: 74
Citation count: 4,456
H-index: 30
I10-index: 41
Year
Topic
Type